Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PQR309 in relapsed or refractory PCNSL
NCT03120000Phase 2Withdrawn
- Sponsor
- PIQUR Therapeutics AG
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 2, open-label trial of bimiralisib in primary central nervous system lymphoma (PCNSL), sponsored by PIQUR Therapeutics AG. Planned start Dec 2017; status: withdrawn.
02
Drugs
bimiralisib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT03120000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03120000.